Chemotherapy for colorectal cancer

Digestive Surgery

Volumn 22, Issue 6, 2006, Pages 401-414

  Goyle, Sandeep ^a   Maraveyas, Anthony ^a  

^a PRINCESS ROYAL HOSPITAL   (United Kingdom)

Author keywords

5 Fluorouracil; Chemotherapy; Colorectal cancer; Irinotecan; Oxaliplatin

Indexed keywords

BEVACIZUMAB; CAPECITABINE; CETUXIMAB; CYCLOOXYGENASE 2 INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; LEVAMISOLE; LOMUSTINE; MITOMYCIN C; OXALIPLATIN; PLACEBO; RALTITREXED; RECOMBINANT VASCULOTROPIN; ROFECOXIB; UFT; VINCRISTINE;

ADVANCED CANCER; ALOPECIA; ANEMIA; ASTHENIA; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER ADJUVANT THERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENTIATION; FEBRILE NEUTROPENIA; FEVER; GASTROINTESTINAL TOXICITY; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; LETHARGY; LEUKOPENIA; METASTASIS; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; NEUTROPENIA; PERIPHERAL NEUROPATHY; QUALITY OF LIFE; REVIEW; SENSORY NEUROPATHY; SEPSIS; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

ANTIMETABOLITES, ANTINEOPLASTIC; CAMPTOTHECIN; CHEMOTHERAPY, ADJUVANT; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DRUG THERAPY, COMBINATION; FLUOROURACIL; HUMANS; LEUCOVORIN; NEOPLASM METASTASIS; ORGANOPLATINUM COMPOUNDS; SURVIVAL RATE; TEGAFUR; URACIL; VITAMIN B COMPLEX;

EID: 33646110275     PISSN: 02534886     EISSN: None     Source Type: Journal    
DOI: 10.1159/000091441     Document Type: Review

References (92)

1. GLOBOCAN 2000: Cancer Incidence, Mortality and Prevalence Worldwide (2000 estimates), 2001.
2. Minsky BD, Mies C, Rich TA, Recht A, Chaffey JT: Potentially curative surgery of colon cancer: the influence of blood vessel invasion. J Clin Oncol 1988;6:119-127.
3. Griffin MR, Bergstralh EJ, Coffey RJ, Beart RW Jr, Melton LJ 3rd: Predictors of survival after curative resection of carcinoma of the colon and rectum. Cancer 1987;60:2318-2324.
4. Bognel C, Rekacewicz C, Mankarios H, et al: Prognostic value of neural invasion in rectal carcinoma: a multivariate analysis on 339 patients with curative resection. Eur J Cancer 1995;31:894-898.
5. Jass JR: The pathological grading and staging of rectal cancer. Scand J Gastroenterol 1988;149(suppl):21-38.
6. Shepherd NA, Saraga EP, Love SB, Jass JR: Prognostic factors in colonic cancer. Histopathology 1989;14:613-620.
7. Fisher ER, Paik SM, Rockette H, et al: Prognostic significance of eosinophils and mast cells in rectal cancer: findings from the National Surgical Adjuvant Breast and Bowel Project (Protocol R-01). Hum Pathol 1989;20:159-163.
8. Gagliardi G, Stepniewska KA, Hershman MJ, et al: New grade-related prognostic variable for rectal cancer. Br J Surg 1995;82:599-602.
9. Saccani Jotti G, Fontanesi M, Orsi N, et al: DNA content in human colon cancer and non-neoplastic adjacent mucosa. Int J Biol Markers 1995;10:11-16.
10. Sinicrope FA, Hart J, Hsu HA, et al: Apoptotic and mitotic indices predict survival rates in lymph node-negative colon carcinomas. Clin Cancer Res 1999;5:1793-1804.
11. Lanza G, Matteuzzi M, Gafa R, et al: Chromosome 18q allelic loss and prognosis in stage II and III colon cancer. Int J Cancer 1998;79:390-395.
12. Ogunbiyi OA, Goodfellow PJ, Herfarth K, et al: Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998;16:427-433.
13. Colorectal Cancer Collaborative Group: Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000;321:531-535.
14. Advanced Colorectal Cancer Meta-Analysis Project: Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992;10:896-903.
15. Expectancy or primary chemotherapy in patients with advanced asymptomatic colorectal cancer: a randomized trial. Nordic Gastrointestinal Tumour Adjuvant Therapy Group. J Clin Oncol 1992;10:904-911.
16. Lokich JJ, Ahlgren JD, Gullo JJ, et al: A prospective randomised comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a Mid Atlantic Oncology Program Study. J Clin Oncol 1989;7:425-432.
17. Colorectal Cancer Meta-Analysis Project: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-Analysis Group in Cancer. J Clin Oncol 1998;16:301-308.
18. Aranda E, Cervantes A, Carrato A, et al: Outpatient weekly high dose continuous infusion 5FU plus oral leucovorin in advanced colorectal cancer. A phase II trial. Spanish Cooperative Group for Gastrointestinal Tumour Therapy. Ann Oncol 1996;7:581-585.
19. Aranda E, Diaz-Rubio E, Cervantes A, et al: Randomised trial comparing monthly low dose leucovorin and fluorouracil bolus with weekly high dose 48 hour continuous infusion fluorouracil for advanced colorectal cancer: a Spanish Cooperative Group for Gastrointestinal Tumour Therapy study. Ann Oncol 1998;9:727-731.
20. Kohne CH, Schoffski P, Wilke H, et al: Biochemical modulation of weekly high dose infusional 5FU in patients with advanced colorectal cancer. Results of a multicentre randomised AIO trial (abstract 963). Proc Annu Meet Am Soc Clin Oncol, 1997, vol 16.
21. de Gramont A, Louvet C, André T, et al: A review of GERCOD trials of bimonthly leucovorin plus 5FU 48 hour continuous infusion in advanced colorectal cancer: evolution of a regimen. Groupe d'Etude et de Recherche sur les Cancers de l'Ovaire et Digestifs (GERCOD). Eur J Cancer 1998;34:619-626.
22. de Gramont A, Bosset JF, Milan C, et al: Randomised trial comparing monthly low dose leucovorin and fluorouracil bolus with bimonthly high dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French Intergroup study. J Clin Oncol 1997;15:808-815.
23. Maughan TS, James RD, Kerr DJ, et al: Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomised trial. Lancet 2002;359:1555-1563.
24. Douillard JY, Hoff PM, Skillings JR, et al: Multicenter phase III study of uracil/tegafur and oral leucovorin vs. fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3605-3616.
25. Carmichael J, Popiela T, Radstone D, et al: Randomized comparative study of tegafur/uracil and oral leucovorin vs. parenteral fluorouracil and leucovorin in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2002;20:3617-3627.
26. Cassidy J, Twelves C, Van Cutsem E, et al: First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002;13:566-575.
27. National Institute of Clinical Excellence: Technology Appraisal, 2003, pp 1-25.
28. Cunningham D, Pyrhonen S, James RD, et al: Randomised trial of irinotecan plus supportive care vs. supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998;352:1413-1418.
29. Rougier P, Van Cutsem E, Bajetta E, et al: Randomised trial of irinotecan vs. fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998;352:1407-1412.
30. Douillard JY, Cunningham D, Roth AD, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet 2000;355:1041-1047.
31. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
32. Kohne CH, Van Cutsem E, Wils JA, et al: Irinotecan improves the activity of the AIO regimen in metastatic colorectal cancer: Results of EORTC GI Group study 40986 (abstract 1018). Proc Am Soc Clin Oncol 2003;22:254.
33. Machover D, Diaz-Rubio E, de Gramont A, et al: Two consecutive phase II studies of oxaliplatin for treatment of patients with advance colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996;7:95-98.
34. de Gramont A, Vignoud J, Touringand C, et al: Oxaliplatin with high-dose leucovorin and 5-fluorouracil 48-hours continuous infusion in pretreated metastatic colorectal cancer. Eur J Cancer 1997;33:214-219.
35. Maindrault-Goebel F, de Gramont A, Louvet C, et al: Evaluation of oxaliplatin dose-intensity with the bimonthly 48 h leucovorin and 5-fluorouracil regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR). Ann Oncol 2000;11:1477-1483.
36. Levi F, Misset JL, Brienza S, et al: A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid and oxaliplatin using an ambulatory multichannel programmable pump. High antitumour effectiveness against metastatic colorectal cancer. Cancer 1992;69:893-900.
37. Garufi C, Brienza S, Pugliese P, et al: Overcoming resistance to chronomodulated 5-fluorouracil and folinic acid by the addition of the chronomodulated oxaliplatin in advanced colorectal cancer patients. Anticancer Drugs 2000;11:495-501.
38. Van Cutsem E, Szanko J, Roth A, et al: Evaluation of the addition of oxaliplatin (OXA) to the same Mayo or German 5FU regimen in advanced refractory colorectal cancer (ARCRC) (abstract 900). Proc Am Soc Clin Oncol 1999, vol 18.
39. Van Cutsem E, Rougier P, Droz JP, et al: Clinical benefit of irinotecan in metastatic colorectal cancer resistant to 5FU (abstract 950). Proc Am Soc Clin Oncol 1997, vol 16.
40. de Gramont A, Figer A, Seymour M, et al: Leucovorin and 5-fluorouracil with or without oxaliplatin as first line treatment in advanced colorectal cancer. J Clin Oncol 2000;18:2938-2947.
41. Giacchetti S, Perpoint B, Zidani R, et al: Phase III multicenter randomized trial of oxaliplatin added to chronomodulated flurouracil-leucovorin as first line treatment of metastatic colorectal cancer. J Clin Onocol 2000;18:136-147.
42. Grothey A, Deschler B, Kroening H, et al: Phase III study of bolus 5-fluorouracil (5-FU)/folinic acid (FA) (Mayo) vs. weekly high-dose 24h 5-FU infusion/FA + oxaliplatin (OXA) (FUFOX) in advanced colorectal cancer (ACRC) (abstract 512). Proc Am Soc Clin Oncol 2002;21:129a.
43. Giacchetti S, Itzhaki M, Gruia G, et al: Longterm survival of patients with unresectable colorectal cancer liver metastases following infusional chemotherapy with 5-fluorouracil, leucovorin, oxaliplatin and surgery. Ann Oncol 1999;10:663-669.
44. Adam R, Avisar E, Ariche A, et al: Five-year survival following hepatic resection after neoadjuvant therapy for nonresectable colorectal. Ann Surg Oncol 2001;8:347-353.
45. Seitz JF, Ferner H, Giovannini M, et al: 5-Fluorouracil, high dose folinic acid and mitomycin C combination chemotherapy in previously treated patients with advanced colorectal carcinoma. J Chemother 1998;10:258-265.
46. Chester JD, Dent JT, Wilson G, et al: Protracted infusion 5-fluorouracil with bolus mitomycin in 5FU-resistant colorectal cancer. Ann Oncol 2000;11:235-237.
47. Price TJ, Ross PJ, Hickish T, et al: Phase III study of mitomycin-C with protracted venous infusion or circadian timed infusion of 5-fluorouracil in advanced colorectal carcinoma. Clin Colorectal Cancer 2004;3:235-242.
48. Sobrero A, Guglielmi A, Cirillo M, et al: 5-Fluorouracil modulated by leucovorin, methotrexate and mitomycin: highly effective, low cost chemotherapy for advanced colorectal cancer. Br J Cancer 2001;84:1023-1028.
49. Goldberg RM, Sargent DJ, Morton RF, et al: A randomised controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 2004;22:23-30.
50. Tournigand C, Andre T, Achille E, et al: FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004;22:229-237.
51. Seymour M: Fluorouracil, oxaliplatin and CPT-11 (irinotecan), use and sequencing (MRC FOCUS): a 2135-patient randomized trial in advanced colorectal cancer (ACRC) (abstract 3518). Am Soc Clin Oncol Annu Meet, 2005.
52. National Institute for Clinical Excellence Appraisal Consultation Document: Irinotecan, Oxaliplatin and Raltitrexed for the Treatment of Advanced Colorectal Cancer. Review of Existing Guidance No. 33.
53. Ellis LM, Takahashi Y, Liu W, Shaheen RM: Vascular endothelial growth factor in human colon cancer: biology and therapeutic implications. Oncologist 2000;5(suppl 1):11-15.
54. Kumar H, Heer K, Lee PW: Preoperative serum vascular endothelial growth factor can predict stage in colorectal cancer. Clin Cancer Res 1998;4:1279-1285.
55. Gordon MS, Margolin K, Talpaz M, et al: Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer. J Clin Oncol 2001;19:843-850.
56. Margolin K, Gordon MS, Holmgren E, et al: Phase Ib trial of intravenous recombinant humanised monoclonal antibody to vascular endothelial growth factor in combination with chemotherapy in patients with advanced cancer: pharmacologic and long-term safety data. J Clin Oncol 2001;19:851-856.
57. Kabbinavar F, Hurwitz HI, Fehrenbacher L, et al: Phase II, randomised trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003;21:60-65.
58. Hurwitz H, Fehrenbacher L, Novotny W, et al: Bevacizumab plus irinotecan, fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 2004;350:2335-2342.
59. Fong TA, Shawver LK, Sun L, et al: SU5416 is a potent and selective inhibitor of the vascular endothelial growth factor receptor (Flk-1/KDR) that inhibits tyrosine kinase catalysis, tumour vascularization and growth of multiple tumour types. Cancer Res 1999;59:99-106.
60. Rosen P, Amado R, Hecht J, et al: A phase I/II study of SU5416 in combination with 5-FU/leucovorin in patients with metastatic colorectal cancer (abstract 5D). Proc Am Soc Clin Oncol, 2000, vol 19.
61. Miller LL, Elfring GL, Hannah AL, et al: Efficacy results of a phase I/II study of SU5416 (S)/5-flurouracil (F)/leucovorin (L) relative to results in random subsets of similar patients (Pts) from a phase III study of Irinotecan (C)/F/L or F/L alone in the therapy of previously untreated metastatic colorectal cancer(MCRC) (abstract 571). Proc Am Soc Clin Oncol, 2001, vol 20.
62. Saltz LB, Cox JV, Blanke C, et al: Irinotecan plus flurouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med 2000;343:905-914.
63. Mayer A, Takimoto M, Fritz E, et al: The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor and mdr gene expression in colorectal cancer. Cancer 1993;71:2454-2460.
64. Saltz L, Rubin M, Hochster H, et al: Cetuximab (IMC-C225) plus Irinotecan (CPT-11) is active in CPT-11 refractory colorectal cancer (CRC) that expresses epidermal growth factor receptor (abstract 7). Proc Am Soc Clin Oncol, 2001, vol 20.
65. Cunningham D, Humblet Y, Siena S, et al: Cetuximab (C225) alone or in combination with irinotecan (CPT-11) in patients with epidermal growth factor receptor (EGFR)-positive, irinotecan-refractory metastatic colorectal cancer (MCRC) (abstract 1012). Proc Am Soc Clin Oncol 2003;22:252.
66. Kargman SL, O'Neill GP, Vickers PJ, et al: Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res 1995;55:2556-2559.
67. Oshima M, Dinchuk JE, Kargman SL, et al: Suppression of intestinal polyposis in Apc delta 716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996;87:803-809.
68. Elder DJ, Halton DE, Hague A, et al: Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2) selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression. Clin Cancer Res 1997;3:1679-1683.
69. Tsujii M, Kawano S, Tsuji S, et al: Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998;93:705-716.
70. Wolmark N, Fisher B, Rockette H, et al: Postoperative adjuvant chemotherapy or BCG for colon cancer: results from NSABP protocol C-01. J Natl Cancer Inst 1988;80:30-36.
71. Laurie JA, Moertel CG, Fleming TR, et al: Surgical adjuvant therapy of large-bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. The North Central Cancer Treatment Group and the Mayo Clinic. J Clin Oncol 1989;7:1447-1456.
72. Moertel CG, Fleming TR, Macdonald JS, et al: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995;122:321-326.
73. Wolmark N, Rockette H, Fisher B, et al: The benefit of leucovorin modulated fluorouracil as postoperative adjuvant therapy for primary colon cancer: results from National Surgical Adjuvant Breast and Bowel Project protocol C-03. J Clin Oncol 1993;11:1879-1887.
74. IMPACT: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995;345:939-944.
75. Haller DG, Catalano PJ, Macdonald JS, et al: Fluorouracil (FU), leucovorin and levamisole adjuvant therapy for colon cancer: Five year report of INT-0089 (abstract). Proc Am Soc Clin Oncol 1998;17:256a.
76. Wolmark N, Rockette H, Mamounas E, et al: Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999;17:3553-3559.
77. O'Connell MJ, Laurie JA, Kahn M, et al: Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998;16:295-300.
78. Comparison of fluorouracil with additional levamisole, higher-dose folinic acid, or both, as adjuvant chemotherapy for colorectal cancer: a randomised trial. QUASAR Collaborative Group. Lancet 2000;355:1588-1596.
79. Kerr DJ, Gray R, McConkey C, et al: Adjuvant chemotherapy with 5-fluorouracil, L-folinic acid and levamisole for patients with colorectal cancer: non-randomised comparison of weekly vs. four-weekly schedules - less pain, same gain. QUASAR Colorectal Cancer Study Group. Ann Oncol 2000;11:947-955.
80. Saini A, Norman AR, Cunningham D, et al: Twelve weeks of protracted venous infusion of fluorouracil (5-FU) is as effective as 6 months of bolus 5-FU and folinic acid as adjuvant treatment in colorectal cancer. Br J Cancer 2003;88:1859-1865.
81. Mamounas E, Wieand S, Wolmark N, et al: Comparative efficacy of adjuvant chemotherapy in patients with Dukes B vs. Dukes C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C01, C02, C03 and C04). J Clin Oncol 1999;17:1349-1355.
82. Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999;17:1356-1363.
83. Figueredo A, Charette M, Maroun J, et al: Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in evidence-based care's gastrointestinal cancer disease site group. J Clin Oncol 2004;22:3395-3407.
84. Benson Al B III, Schrag D, Somerfield M, et al: American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004;22:3408-3419.
85. Gray RG, Barnwell J, Hills R, et al: QUASAR: a randomised study of adjuvant chemotherapy vs. observation including 3238 colorectal cancer patients (abstract 3501). J Clin Oncol 2004;22:14S.
86. Wolmark N, Wieand S, Lembersky B, et al: A phase III trial comparing oral UFT to FULV in stage II and III carcinoma of the colon: Results of NSABP Protocol C-06 (abstract 3508). J Clin Oncol 2004;22:14S.
87. Cassidy J, Scheithauer W, McKendrick J, et al: Capecitabine vs. bolus 5FU/LV as adjuvant therapy for colon cancer (the X-ACT study): positive efficacy results of a phase III trial (abstract 3509). J Clin Oncol 2004;22:14S.
88. Andre T, Boni C, Mounedji-Boudiaf L, et al: Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer (MOSAIC) Investigators: Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004;350:2343-2351.
89. Hickish T, Boni C, Navarro M, et al: FOLFOX4 as adjuvant treatment for stage II colon cancer: subpopulation data from the MOSAIC trial (abstract 3619). J Clin Oncol 2004;22:14S.
90. Saltz LB, Niedzwiecki D, Hollis D, et al: Irinotecan plus fluorouracil/leucovorin (IFL) vs. fluorouracil/leucovorin alone in stage III colon cancer (Intel-group trial CALGB C89803) (abstract 3500). J Clin Oncol 2004;22:14S.
91. Popescu RA, Norman A, Ross PJ, Parikh B, Cunningham D: Adjuvant or palliative chemotherapy for colorectal cancer in patients 70 years or older. J Clin Oncol 1999;17:2412-2418.
92. Schrag D: The price tag on progress - chemotherapy for colorectal cancer. N Engl J Med 2004;351:317-319.